Another—albeit much smaller (n = 40)—study also found that PD-L1 expression on circulating tumor cells may also be a predictive biomarker for PD-1 inhibitor response, suggesting that liquid biopsy may provide clinically relevant information during treatment selection [115]. The gene discussed is PDCD1; the disease is neoplasm.